Annexon Stock
Annexon, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Douglas E. Love
- Employees
- 92
- Market cap
- $559 M
- IPO
- 24/07/2020
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The…
Annexon stock: price history
1D
-5.3%
1W
-15.2%
1M
-13.2%
6M
-47.9%
YTD
-32.1%
1Y
+7.6%
2Y
-55.2%
5Y
-84.5%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~15% weaker price swings than usual
Ask the agents about Annexon
Analyst assessment of Annexon
PRICE TARGET LOW
US$7.00
CONSENSUS
US$10.50
MEDIAN
US$10.50
PRICE TARGET HIGH
US$14.00
0
STRONG BUY
10
BUY
1
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 30/09/2026
Annexon stock metrics
P/E
-2.94
P/B
3.68
EV/EBITDA
-1.92
RETURN ON EQUITY
-29.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
107.2%
FLOAT SHARES
175,573,139
AVG. DAILY VOLUME (30D)
3,407,749
Insider transactions (SEC)
Love Douglas
Yednock Ted
Satter Muneer A
Carson William H.
Institutional holders
Comparable stocks
Frequently asked questions about Annexon stock
What does Annexon do?
Annexon, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Douglas E. Love, the company employs around 92 people.
The IPO was on 24/07/2020; the stock trades on NASDAQ under the ticker ANNX.
What do analysts say about Annexon stock?
11 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$10.50, ranging from US$7.00 to US$14.00, with a median of US$10.50.
This is an external assessment, not a statement by Market Jury.
When does Annexon report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -15% stronger than usual.
Does Annexon pay a dividend?
No, Annexon currently does not pay a dividend.
Which stocks are comparable to Annexon?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Annexon stock analyzed?
Clicking "Analyze stock" lets five strategies assess Annexon against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.